{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:35:32Z","timestamp":1764729332201,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370179"],"award-info":[{"award-number":["82370179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key R&D Program of China, Ministry of Science and Technology of the People's Republic of China","award":["2022YFC2304605"],"award-info":[{"award-number":["2022YFC2304605"]}]},{"name":"Beijing Natural Science Haidian frontier Foundation","award":["L222081"],"award-info":[{"award-number":["L222081"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06707-1","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T03:34:03Z","timestamp":1762745643000},"page":"5669-5676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Dabrafenib in Erdheim-Chester disease"],"prefix":"10.1007","volume":"104","author":[{"given":"Zheng-zheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-lei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"13","key":"6707_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/blood.2023020569","volume":"142","author":"F Pegoraro","year":"2023","unstructured":"Pegoraro F, Mazzariol M, Trambusti I et al (2023) Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients. Blood 142(13):1167\u20131171. https:\/\/doi.org\/10.1182\/blood.2023020569","journal-title":"Blood"},{"key":"6707_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102658","volume":"73","author":"F Pegoraro","year":"2024","unstructured":"Pegoraro F, Papo M, Cohen-Aubart F et al (2024) Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans cell histiocytosis). EClinicalMedicine 73:102658. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102658","journal-title":"EClinicalMedicine"},{"issue":"12","key":"6707_CR3","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1007\/s00277-023-05501-1","volume":"102","author":"JW Dai","year":"2023","unstructured":"Dai JW, Lin H, Chang L et al (2023) The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease. Ann Hematol 102(12):3335\u20133343. https:\/\/doi.org\/10.1007\/s00277-023-05501-1","journal-title":"Ann Hematol"},{"key":"6707_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015399","author":"F Pegoraro","year":"2025","unstructured":"Pegoraro F, Catamero F, Peyronel F et al (2025) Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2024015399","journal-title":"Blood Adv"},{"issue":"6","key":"6707_CR5","doi-asserted-by":"publisher","first-page":"102038","DOI":"10.1016\/j.esmoop.2023.102038","volume":"8","author":"JY Blay","year":"2023","unstructured":"Blay JY, Cropet C, Mansard S et al (2023) Long term activity of Vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF(V600)-mutated melanoma [J]. ESMO Open 8(6):102038. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102038","journal-title":"ESMO Open"},{"issue":"3","key":"6707_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC et al (2018) Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4(3):384\u2013388. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5029","journal-title":"JAMA Oncol"},{"issue":"5","key":"6707_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche J, Cohen-Aubart F, Emile JF et al (2015) Reproducible and sustained efficacy of targeted therapy with Vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease [J]. J Clin Oncol 33(5):411\u2013418. https:\/\/doi.org\/10.1200\/JCO.2014.57.1950","journal-title":"J Clin Oncol"},{"key":"6707_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/DDDT.S38998","volume":"6","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Long GV, Murali R (2012) Dabrafenib and its potential for the treatment of metastatic melanoma [J]. Drug Des Devel Ther 6:391\u2013405. https:\/\/doi.org\/10.2147\/DDDT.S38998","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"6707_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdt587","volume":"25","author":"B Schilling","year":"2014","unstructured":"Schilling B, Sondermann W, Zhao F et al (2014) Differential influence of Vemurafenib and Dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 25(3):747\u2013753. https:\/\/doi.org\/10.1093\/annonc\/mdt587","journal-title":"Ann Oncol"},{"issue":"8","key":"6707_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","volume":"1","author":"KD Jhaveri","year":"2015","unstructured":"Jhaveri KD, Sakhiya V, Fishbane S (2015) Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol 1(8):1133\u20131134. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1713","journal-title":"JAMA Oncol"},{"issue":"5","key":"6707_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/bjd.13522","volume":"172","author":"G Jeudy","year":"2015","unstructured":"Jeudy G, Dalac-Rat S, Bonniaud B et al (2015) Successful switch to Dabrafenib after vemurafenib-induced toxic epidermal necrolysis [J]. Br J Dermatol 172(5):1454\u20131455. https:\/\/doi.org\/10.1111\/bjd.13522","journal-title":"Br J Dermatol"},{"key":"6707_CR12","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.935090","volume":"23","author":"H Salama","year":"2022","unstructured":"Salama H, Fahed Alzayed M, Alharbi KG et al (2022) Erdheim-Chester disease successfully treated with front-line single-agent dabrafenib. Am J Case Rep 23:e935090. https:\/\/doi.org\/10.12659\/AJCR.935090","journal-title":"Am J Case Rep"},{"issue":"6","key":"6707_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.20452\/pamw.4284","volume":"128","author":"G Verschelden","year":"2018","unstructured":"Verschelden G, Van Laethem J, Velkeniers B et al (2018) Significant response to Dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation. Pol Arch Intern Med 128(6):386\u2013388. https:\/\/doi.org\/10.20452\/pamw.4284","journal-title":"Pol Arch Intern Med"},{"issue":"22","key":"6707_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal G, Heaney ML, Collin M et al (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135(22):1929\u20131945. https:\/\/doi.org\/10.1182\/blood.2019003507","journal-title":"Blood"},{"key":"6707_CR15","doi-asserted-by":"publisher","first-page":"1505951","DOI":"10.3389\/fonc.2024.1505951","volume":"14","author":"SS McThenia","year":"2024","unstructured":"McThenia SS, Reddy KM, Damaraju E et al (2024) BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center\u2019s experience [J]. Front Oncol 14:1505951. https:\/\/doi.org\/10.3389\/fonc.2024.1505951","journal-title":"Front Oncol"},{"issue":"9","key":"6707_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0827-x","volume":"21","author":"V Vanella","year":"2019","unstructured":"Vanella V, Festino L, Trojaniello C et al (2019) The role of BRAF-targeted therapy for advanced melanoma in the immunotherapy era. Curr Oncol Rep 21(9):76. https:\/\/doi.org\/10.1007\/s11912-019-0827-x","journal-title":"Curr Oncol Rep"},{"issue":"22","key":"6707_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood.V128.22.480.480","volume":"128","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Subbiah V, Lockhart C et al (2016) Vemurafenib in patients with Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) harboring BRAFV600 mutations: a cohort of the Histology-Independent VE-Basket study [J]. Blood 128(22):480\u2013480. https:\/\/doi.org\/10.1182\/blood.V128.22.480.480","journal-title":"Blood"},{"issue":"4","key":"6707_CR18","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.3324\/haematol.2017.185298","volume":"103","author":"A Bhatia","year":"2018","unstructured":"Bhatia A, Ulaner G, Rampal R et al (2018) Single-agent Dabrafenib for BRAF(V600E)-mutated histiocytosis. Haematologica 103(4):e177\u2013e180. https:\/\/doi.org\/10.3324\/haematol.2017.185298","journal-title":"Haematologica"},{"issue":"1","key":"6707_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010141","volume":"15","author":"M Garutti","year":"2022","unstructured":"Garutti M, Bergnach M, Polesel J et al (2022) BRAF and MEK inhibitors and their toxicities: a meta-analysis. Cancers (Basel) 15(1):141. https:\/\/doi.org\/10.3390\/cancers15010141","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06707-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06707-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06707-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:30:45Z","timestamp":1764729045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06707-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6707"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06707-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study conducted in accordance with the 1964 Declaration of Helsinki and its subsequent revisions. Ethical approval and waivers of informed consent were obtained from the Peking Union Medical College Hospital Ethics Committee and Cancer Hospital Chinese Academy of Medical Science Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}